7A674726-107E-461B-9DAB-CAE728B8B129
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.588699080157687
- age_years
- 35
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.529
- NOTCH_SIGNALING+0.438
- WNT_BETA_CATENIN_SIGNALING+0.366
- MYC_TARGETS_V1+0.364
- MYC_TARGETS_V2+0.363
- DNA_REPAIR+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.323
- HEDGEHOG_SIGNALING+0.301
- PANCREAS_BETA_CELLS+0.275
- ADIPOGENESIS+0.245
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.477
- INTERFERON_GAMMA_RESPONSE-0.428
- INTERFERON_ALPHA_RESPONSE-0.386
- INFLAMMATORY_RESPONSE-0.311
- TNFA_SIGNALING_VIA_NFKB-0.289
- ALLOGRAFT_REJECTION-0.288
- COAGULATION-0.274
- MYOGENESIS-0.227
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.226
- COMPLEMENT-0.214
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 87F9E756-60BB-435B-9A2D-211E89C182D9 | — | — | 0.883 |
| 2 | E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18 | — | — | 0.848 |
| 3 | D1BFDB5B-3131-4B5C-8090-B3B91D4450F3 | — | — | 0.834 |
| 4 | SRR934796 | — | — | 0.826 |
| 5 | BS_WGK8ZMVA | Supratentorial Ependymoma | — | 0.817 |
| 6 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.816 |
| 7 | 28E176DE-49DB-4F39-B022-C89235590CAC | — | — | 0.810 |
| 8 | R277 | — | — | 0.808 |
| 9 | B71EF25E-7DDB-42DA-84A5-920A90E85512 | — | — | 0.807 |
| 10 | SRR8392895 | — | cohortSQ2 | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.529 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.438 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.366 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.364 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.363 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.323 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.301 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.275 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.245 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.234 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.203 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.189 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.185 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.184 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.179 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.172 | Inavolisib | — uncovered |
| PEROXISOME | 0.172 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.167 | Idelalisib | — uncovered |